categories: CD and Related Antigens (Human)

Mouse Monoclonal to CD79b

CB3-1 (IgG1)

Product No.	Form	Quantity	Price
11-676-C025	purified	0.025 mg	choose region
11-676-C100	purified	0.1 mg	choose region
1F-676-T025	FITC	25 tests	choose region
1F-676-T100	FITC	100 tests	choose region
1P-676-T025	PE	25 tests	choose region
1P-676-T100	PE	100 tests	choose region
T9-676-T025	PerCP-Cy™5.5	25 tests	choose region
T9-676-T100	PerCP-Cy™5.5	100 tests	choose region

- In stock! Ready for immediate despatch

- Manufacture on order

Background

CD79b (Ig beta, B29) forms disulfide-linked heterodimer with CD79a (Ig alpha, MB1). They both are transmembrane proteins with extended cytoplasmic domains containing immunoreceptor tyrosine activation motives (ITAMs), and together with cell surface immunoglobulin they constitute B-cell antigen-specific receptor (BCR). CD79a and b are the first components of BCR that are expressed developmentally. They appear on pro-B cells in association with the endoplasmic reticulum chaperone calnexin. Subsequently, in pre-B cells, CD79 heterodimer is associated with lambda5-VpreB surrogate immunoglobulin and later with antigen-specific surface immunoglobulins. CD79a/b complex interacts with Src-family tyrosine kinase Lyn, which phosphorylates its cytoplasmic ITAM motives to form docking sites for downstream signaling.

Entrez Gene: 17q23

Specificity

The mouse monoclonal antibody CB3-1 recognizes an extracellular epitope of CD79b (CD79 beta, Ig beta), an approximately 38 kDa component of B cell receptor (BCR) complex.
HLDA VI.; WS Code CD79.1

Immunogen

Fraction of Ig-associated molecules isolated from Ramos B cells

Species Reactivity: Human Negative Species:	Applications: Flow Cytometry Immunoprecipitation Western Blotting Usage note: Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.	Product Specific References Nakamura T, Kubagawa H, Cooper MD: Heterogeneity of immunoglobulin-associated molecules on human B cells identified by monoclonal antibodies. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8522-6. [Abstract] [Full Text] Zheng B, Fuji RN, Elkins K, Yu SF, Fuh FK, Chuh J, Tan C, Hongo JA, Raab H, Kozak KR, Williams M, McDorman E, Eaton D, Ebens A, Polson AG: In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. Mol Cancer Ther. 2009 Oct;8(10):2937-46. [Abstract] [Full Text] Garcia Vela J, Delgado I, Benito L, Monteserin M, Garcia Alonso L, Somolinos N, Andreu M, Oña F: CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection. Leukemia. 1999 Oct;13(10):1501-5. [Abstract] Rassenti LZ, Kipps TJ: Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. Blood. 2000 Apr 15;95(8):2725-7. [Abstract] [Full Text] Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu SF, Yue P, Zheng B, Ebens A, Polson AG: Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009 Sep 24;114(13):2721-9. [Abstract] [Full Text] Matutes E: New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders. J Clin Pathol. 2002 Mar;55(3):180-3. [Abstract] [Full Text] *D'Arena G, Cascavilla N, Musto P, Colella Bisogno R, Pistolese G, Carotenuto M: CD79b expression in B-cell chronic lymphocytic leukemia. Haematologica. 2000 May;85(5):556-7. [Abstract] [Full Text]

Species Reactivity:

Human

Negative Species:

Applications:

Flow Cytometry
Immunoprecipitation
Western Blotting

Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

Product Specific References

*Nakamura T, Kubagawa H, Cooper MD: Heterogeneity of immunoglobulin-associated molecules on human B cells identified by monoclonal antibodies. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8522-6. [Abstract] [Full Text]

*Zheng B, Fuji RN, Elkins K, Yu SF, Fuh FK, Chuh J, Tan C, Hongo JA, Raab H, Kozak KR, Williams M, McDorman E, Eaton D, Ebens A, Polson AG: In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. Mol Cancer Ther. 2009 Oct;8(10):2937-46. [Abstract] [Full Text]

*Garcia Vela J, Delgado I, Benito L, Monteserin M, Garcia Alonso L, Somolinos N, Andreu M, Oña F: CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection. Leukemia. 1999 Oct;13(10):1501-5. [Abstract]

*Rassenti LZ, Kipps TJ: Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. Blood. 2000 Apr 15;95(8):2725-7. [Abstract] [Full Text]

*Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu SF, Yue P, Zheng B, Ebens A, Polson AG: Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009 Sep 24;114(13):2721-9. [Abstract] [Full Text]

*Matutes E: New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders. J Clin Pathol. 2002 Mar;55(3):180-3. [Abstract] [Full Text]

*D'Arena G, Cascavilla N, Musto P, Colella Bisogno R, Pistolese G, Carotenuto M: CD79b expression in B-cell chronic lymphocytic leukemia. Haematologica. 2000 May;85(5):556-7. [Abstract] [Full Text]

For research use only. Not for drug, diagnostic or other use.

PRODUCTS